| TA34 |
Breast cancer - trastuzumab (TA34) |
|
-
-
advanced breast cancer
Fast, easy summary view of NICE guidance on 'advanced breast cancer'
-
-
-
The clinical effectiveness and cost effectiveness of trastuzumab for breast cancer
NICE has recommended that trastuzumab (Herceptin) is used in combination with paclitaxel for women with tumours with excessive human epidermal growth factor receptor 2 (HER2) at levels of 3+ who have not had chemotherapy for metastatic breast cancer and for whom anthracycline treatment is inappropriate.
Trastuzumab by itself is recommended for women with tumours with excessive HER2 at levels of 3+ who have had at least two chemotherapy treatments for metastatic breast cancer. Previous chemotherapy must have included at least an anthracycline drug and a taxane drug where these treatments are appropriate. It should also have included hormonal therapy in patients sensitive to oestrogen.
The level of HER2 protein in the body should be assessed by a clinician using appropriate standards and methods.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: advanced breast cancer
How this guidance was produced
Background information
This page was last updated: 26 October 2011
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
